Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy-Reference-Cited by-同舟云学术

Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy

Published:2006-04 Issue:2 Volume:16 Page:137-145
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Trefzer Uwe,Hofmann Maja,Reinke Susanne,Guo Ya-Jun,Audring Heike,Spagnoli Giulio,Sterry Wolfram

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference41 articles.

1. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients;Reynolds;J Immunol,1998

2. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions;de Vries;Cancer Res,1997

3. The new melanoma markers: MART-1 and Melan-A (the NIH experience);Fetsch;Am J Surg Pathol,1999

4. Heterogeneity of melanoma antigen-1 (MAGE-1) gene and protein expression in malignant melanoma;Zuber;Eur Surg Res,1997

5. Expression of MAGE genes in primary and metastatic cutaneous melanoma;Brasseur;Int J Cancer,1995

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptide nanovaccine in melanoma immunotherapy;International Immunopharmacology;2024-03

2. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells;Molecular Cancer;2023-08-30

3. Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma;Frontiers in Immunology;2022-03-29

4. Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy;Cancers;2021-08-23

5. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors;Targeted Oncology;2021-02-08